Open AccessA Randomized Controlled Trial of Three- versus Five-Day Artemether-Lumefantrine Regimens for Treatment of Uncomplicated Plasmodium falciparum Malaria in Pregnancy in Africa
Author(s) -
Marie Onyamboko,
Richard M Hoglund,
Sue J. Lee,
Charlie Kabedi,
Daddy K. Kayembe,
Benjamin B. Badjanga,
Gareth D. H. Turner,
Nikky V. Jackson,
Joel Tärning,
Rose McGready,
François Nosten,
Nicholas J. White,
Nicholas Day,
Caterina Fanello
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01140-19
Subject(s) - artemether/lumefantrine , artemether , malaria , plasmodium falciparum , lumefantrine , medicine , randomized controlled trial , pregnancy , sulfadoxine/pyrimethamine , pyrimethamine , artemisinin , immunology , biology , genetics
Artemether-lumefantrine antimalarial efficacy in pregnancy could be compromised by reduced drug exposure. Population-based simulations suggested that therapeutic efficacy would be improved if the treatment duration was increased.